|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date24 Sep 2009 |
/ CompletedNot Applicable 亿珂在中国慢性淋巴细胞白血病或小淋巴细胞淋巴瘤初治患者中的治疗模式和治疗反应:一项真实世界数据库的研究
[Translation] Treatment patterns and responses of Yike in treatment-naive Chinese patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a real-world database study
根据国际慢性淋巴细胞白血病工作组(iwCLL)共识指南,估算伊布替尼在CLL/SLL初治患者中的总体反应率(ORR)。
[Translation] The overall response rate (ORR) of ibrutinib in treatment-naïve patients with CLL/SLL was estimated according to the International Working Group on Chronic Lymphocytic Leukemia (iwCLL) consensus guidelines.
/ Active, not recruitingPhase 4 在中国推广和实施HIV暴露前预防(PrEP):武汉和广州高危青少年PrEP示范项目
[Translation] Promoting and implementing HIV pre-exposure prophylaxis (PrEP) in China: PrEP demonstration projects for high-risk adolescents in Wuhan and Guangzhou
目标1:记录两座中国城市中3,200名高危MSM人群和大学年龄段的青年中每天一次使用PrEP的人数 。
目标2:通过对中国两座城市的3,200名高危MSM人群和大学年龄段的青年进行问卷调查,获取他们有关 HIV / STI的风险行为以及有关性行为和使用PrEP的知识,看法和做法。
目标3:获取中国两座城市3,200名MSM和大学年龄段青年梅毒和HIV感染率以及1,200名PrEP使用者中梅毒,淋病,衣原体和HIV感染率的数据。
目标4:确定6个月和12个月时1,200名使用PrEP的人的保留率,依存率和特征。
目标5:通过与选定参与者(n = 30)进行的深入访谈,评估MSM和大学年龄青年中PrEP微信小程序干预的经验。
[Translation] Objective 1: To record the number of people who use PrEP once a day among 3,200 high-risk MSM and college-age youth in two Chinese cities.
Objective 2: To obtain HIV/STI risk behaviors and knowledge, perceptions, and practices regarding sexual behaviors and PrEP use through questionnaire surveys among 3,200 high-risk MSM and college-age youth in two Chinese cities.
Objective 3: To obtain data on syphilis and HIV prevalence among 3,200 MSM and college-age youth and syphilis, gonorrhea, chlamydia, and HIV prevalence among 1,200 PrEP users in two Chinese cities.
Objective 4: To determine retention, adherence, and characteristics of 1,200 PrEP users at 6 and 12 months.
Objective 5: To evaluate the experience of the PrEP WeChat mini-program intervention among MSM and college-age youth through in-depth interviews with selected participants (n = 30).
100 Clinical Results associated with AndersonBrecon, Inc.
0 Patents (Medical) associated with AndersonBrecon, Inc.
100 Deals associated with AndersonBrecon, Inc.
100 Translational Medicine associated with AndersonBrecon, Inc.